

FINAL PROGRAMME

Team

Dedicated
media partner



Partner journal



ABC Award	Dolores Knupfer (2) dknupfer@eso.net
Abstracts	Luis Carvalho (2) lcarvalho@eso.net
Travel grants	Dolores Knupfer (2) dknupfer@eso.net
Registration	Luis Carvalho (2) lcarvalho@eso.net Laura Richetti (2) lrichetti@eso.net
Accommodation, optional tours and social event	Helder Carvalho (3) helder.carvalho@abreu.pt
Organisation, exhibition, satellite symposia and sponsorship	Francesca Marangoni (1) fmarangoni@eso.net
Programme	Dolores Knupfer (2) abc@eso.net Alexandra Zampetti (2) azampetti@eso.net
Social media	Corinne Hall (1) chall@eso.net
Communication	Gabriele Maggini (2) gmaggini@eso.net
Press officers	International media: Emma Mason and Kerry Noble info@ricemason.eu National media: Filipa Morais fm@publicrelations.pt
ABC Global Alliance	Roberta Ventura (2) rventura@eso.net
Coordination	Chatrina Melcher (2) cmelcher@eso.net

1 European School of Oncology Via Turati 29 20121 Milano, Italy	ph +39 02 85464 532 fx +39 02 85464 545 www.abc-lisbon.org www.eso.net
2 European School of Oncology Piazza Indipendenza 2 6500 Bellinzona, Switzerland	ph +41 91 820 0950 fx +41 91 820 0953 www.abc-lisbon.org www.eso.net
3 Viagens Abreu SA Av. 25 de Abril, 2 2799-556 Linda-a-Velha, Portugal	ph +351 21 415 6120 fx +351 21 415 6383

Dear Colleagues,

The International Consensus Conference for Advanced Breast Cancer (ABC) has established itself as a major international breast cancer conference. Its primary aim is the development of international consensus guidelines for the management of ABC patients. These guidelines are based on the most up-to-date evidence and can be used to guide treatment decision making in many different health care settings globally, with the necessary adaptations due to different access to care.

The last meeting, which took place in Lisbon, Portugal in November 2015, brought together over 1.200 participants from 84 countries around the world, including health professionals, patient advocates and journalists.

We believe that health professionals working closely together with patient advocates and with the strong support of media can raise awareness about the needs and challenges faced by this traditionally underserved and forgotten group of patients. ABC also aims to identify research priorities based on the most important areas of unmet need, analyse and discuss available data to provide the most accurate management recommendations, as well as influence policy makers and funding bodies and ultimately improve standards of care, survival and quality of life. Research and education, with accurate usage of available knowledge, throughout the world, are key to achieve these goals.

ABC guidelines are jointly developed by ESO (European School of Oncology) and ESMO (European Society of Medical Oncology) and guidelines or ABC conferences have been endorsed and supported by several other international oncology organizations such as EUSOMA (European Society of Breast Cancer Specialists), ESTRO (European Society of Radiation Oncology), ESGO (European Society of Gynaecological Oncology), UICC (Union International Contre le Cancer), SIS (Senologic International Society) / ISS (International School of Senology), FLAM (Federacion Latino-Americana de Mastologia), OECI (Organization of European Cancer Institutes), Susan G. Komen® and BCRF (Breast Cancer Research Foundation), and have official representation from ASCO.

The recent creation of the ABC Global Alliance, will also provide a much needed platform for the development of important projects, aiming to strongly impact on the survival and quality of life of advanced breast cancer patients.

It is therefore with great enthusiasm that we welcome you to the Advanced Breast Cancer Fourth ESO-ESMO International Consensus Conference (ABC4) taking place in Lisbon, Portugal, on 2-4 November 2017, which will be followed by the first meeting of the ABC Global Alliance on 4 and 5 November 2017.

Fatima Cardoso,

Coordinating Chair

Acknowledgements

The European School of Oncology wishes to express its appreciation and gratitude to the ABC4 Chairs and Scientific Committee members for their support and vision in organising this conference, all faculty members and panellists, and members of the Patient Advocacy Committee for their commitment and contribution to the programme. ESO's gratitude is furthermore extended to *The Breast* and *Cancer World* for their cooperation, all organisations and companies for participating and supporting the initiative.

General information



Venue

ABC4 will be held at the CCL - Centro de Congressos de Lisboa, Praça das Industrias, Lisbon, Portugal.

Official language

The official language will be English. No translation will be provided.

Insurance

The organisers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.

Abstract book

The abstract book is published as a supplement of *The Breast* and contain abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only.

CME accreditation and certificates

Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire.

The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.



The event is designated for a maximum of **15 European CME credits (ECMEC)**. Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.



Furthermore, the conference has been accredited with **17 ESMO-MORA category 1 points**.

Filming, recording or photographing Conference sessions

Filming, recording or photographing Conference sessions is prohibited, unless prior permission has been sought and agreement obtained from the press officers. Filming, recording or photographing in the general areas of the Conference is permitted if prior permission has been sought and agreement obtained from the press officers.

Social media

Follow updates and send questions to our onsite Social Media Moderators using **#ABClisbon** on Twitter and Facebook (@ESOncology) and join in the discussions.

**Internet access**

Free internet Wi-Fi access is available for conference delegates on Level 1.

To access Wi-Fi, please use the following information:

Network name: ESO_ABC - Password: abc42017

Third Party Media Policy

The policy that applies to all activities related to the news media during or in connection with ABC4 and is posted at www.abc-lisbon.org/pagine-interne/third-party-media-policy.html

The aim is to ensure that information distributed to the journalists is accurate and is issued at the correct times, complying with any embargoes that may be in place. The policy applies to media events that are organised at the ABC4 venue and off-site, and all third parties are requested to adhere.

No smoking policy

ABC4 is a tobacco-free event. All participants are kindly asked to respect the no-smoking policy.

Official carrier

ESO is grateful to TAP Portugal, a Star Alliance member, who supported the Conference as the Official Carrier and offered discounted fares to the participants.

Conference speakers and panellists

Conference speakers and panellists are invited to refer to the speakers' room located on Level 1. Presentation files should be delivered to the appointed technician in the speakers' room 30 minutes or more before the start of the session.

Press office

Accredited journalists wearing a "media representative" badge are invited to refer to the press office located on Level 1.

Press Conference

We invite all media representatives to attend the press conference which will be held on Thursday, 2 November from 12:30 to 13:00 in the ESO Meeting room located on Level 1.

Coffee breaks, lunches and welcome cocktail

Coffee breaks, lunches and welcome cocktail are available to all participants, media representatives and exhibitors during the published times. Buffets are organised on Level 1 in the poster and in the catering areas.

Furthermore, please note that the **poster session is scheduled on Friday, 3 November during lunch time.**

During the poster session, the appointed faculty members will visit and discuss the posters with the presenters and participants.

Registration desk, opening hours

Wednesday, 1 November	14:00 - 17:00
Thursday, 2 November	8:30 - 20:00
Friday, 3 November	8:30 - 20:00
Saturday, 4 November	8:00 - 13:30

Exhibition, opening hours

Thursday, 2 November	9:00 - 19:30
Friday, 3 November	9:00 - 19:30
Saturday, 4 November	8:30 - 13:00

Registration

Admission to the sessions is granted to faculty members, panellists, participants and media representatives who hold a full registration. Furthermore, registration grants a copy of the programme and of the abstract book, coffee breaks, lunches, welcome cocktail as indicated in the programme. Representatives of exhibiting companies do not have access to the sessions but to all other services.

Regular registration fees	Early (30 July)	Late (by 15 October)	On-site (from 16 October)
Registration fee	EUR 450	EUR 550	EUR 700
Club ESO Members	EUR 350		
ESMO Members	EUR 350		

Badge

The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

Cancellation

Replacements or refund of registration fees (less handling charges) was possible for notification to ESO by 10 October.

Nurses and patient advocates

Nurses and representatives of cancer patient advocacy non-profit organisations are eligible for a discounted registration fee:

EUR 250 by 30 July

EUR 300 by 15 October

EUR 400 from 16 October 2017 and on-site.

To register to the Conference, nurses and representatives of patient advocacy organisations should submit the following documents:

- Nurses: curriculum vitae with full contact details
- Patient advocates: curriculum vitae or resume indicating the advocacy experience, role within the organisation and the full contact details of the patient advocate organisation.

Media registration

The Conference welcomes representatives of print and electronic media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Representatives of advertising, marketing and public relations companies are not eligible for free media registration. A copy of the Press Card or of the commissioning letter should be sent together with the media registration form.

Group registration

The group registration procedure was available for groups of 5 or more individuals, and foresees that the group leader's instructions regarding the collection of the on-site materials (badge, delegates bag) are followed. For any query, please refer to the group registration desk on-site.

Registration to the first meeting of the ABC Global Alliance

ABC4 registered participants are cordially invited to attend the meeting that will take place on Saturday, 4 November, from 15:00 to 18:00 and Sunday, 5 November from 09:00 to 13:00.

For further information about the ABC Global Alliance, please visit www.abcgloballiance.org.

Public transportation and passes

Public transportation is available from the hotels and the congress centre.

HOTEL	Distance Km/time	Public transportation
Pestana Palace	0,8/8'	(walking dist)
Jeronimos 8	2,5/15'	A
Vila Gale Opera	0,3/3'	(walking dist)
Tivoli Lisboa	5/20'	B
Jeronimos 8,	5/20'	B
Vila Gale Opera	5/20'	B

A Tram 15 or Bus 751
Belem ↔ Praça do Comercio (city centre)

B From hotel to venue, bus 732
Avenida da Liberdade ↔ Caselas

The stop at the Congress Centre is "Rua Junqueira".

A limited number of **free public transportation passes** (with 6 tickets for metro and bus) are available for ABC4 participants and will be distributed from the Abreu desk on a first-come/first-served basis.

Airport Transportation

Aerobus - Lisbon Airport Transfer Bus - has regular links between airport and important points in the city. This custom service is composed of dedicated and helpful staff, free Wi-Fi, USB chargers and stops at the main hotels, running daily between 7:30am and 11pm.

To check your hotel line, please visit: <https://www.aerobus.pt/en-GB>

High Patronage



The European School of Oncology is proud to announce that the Conference is held under the High Patronage of His Excellency the President of the Portuguese Republic and is honoured that His Excellency the President of the Portuguese Republic, Prof. Marcelo Rebelo de Sousa, will welcome ABC4 participants to Lisbon and open the Conference.

ABC4 Scientific Committee

Coordinating chair



Fatima Cardoso

Breast Unit,
Champalimaud Clinical Center,
Lisbon, PT

Co-chairs



Elzbieta Senkus

Dept. of Oncology and Radiotherapy,
Medical University of Gdansk,
Gdansk, PL



Evi Papadopoulos

Europa Donna,
Nicosia, CY

Chairs




Eric P. Winer

Breast Oncology Center,
Dana-Farber Cancer Institute,
Boston, US



Larry Norton

Breast Cancer Programs,
Memorial Sloan-Kettering Cancer Centre,
New York, US



Alberto Costa


European School of Oncology,
Milan, IT and Bellinzona, CH

Scientific Committee Members



Matti S. Aapro

MO Clinique de Genolier,
Institut Multidisciplinaire d'Oncologie,
Genolier, CH



Fabrice André

Department of Medical Oncology,
Gustave Roussy Institute,
Villejuif, FR



Nadia Harbeck

Breast Centre,
University of Munich,
Munich, DE



ABC4 is held in memory of ...

Doris Fenech, a passionate breast cancer nurse, a dedicated patient advocate and an advanced breast cancer patient who strongly believed in and supported the ABC Consensus Conferences serving in its committee from the beginning.

Faculty members

Bertha Aguilar Lopez

ULACCAM, Mexico City, MX

Carlos H. Barrios

Department of Medicine, PUCRS School of Medicine,
Porto Alegre, BR

Jonas Bergh

Department of Oncology-Pathology, Karolinska Institute,
Stockholm, SE

Elizabeth Bergsten Nordström

Swedish Breast Cancer Association, Stockholm, SE

Laura Biganzoli

Department of Medical Oncology, Sandro Pitigliani
Oncology Centre, Prato, IT

Christine B. Boers-Doets

CB Boers ORG. Wormer, NL and The Netherlands Leiden
University Medical Center, Leiden, NL

Anna Cabanes

Susan G. Komen, Washington, US

Maria João Cardoso

Breast Unit, Champalimaud Cancer Center and
MamaHelp, Lisbon, PT

Lisa A. Carey

Department of Hematology and Oncology, UNC
Lineberger Comprehensive Cancer Center, North
Carolina, US

Dian "CJ" M. Corneliussen-James

METAvisor Research and Support, Annapolis, US

Javier Cortés

Ramón y Cajal University Hospital, Madrid & Vall
d'Hebron Institute of Oncology (VHIO), Madrid, ES

Giuseppe Curigliano

Division of Experimental Therapeutics, European Institute
of Oncology, Milan, IT

Véronique Diéras

Gynaecology and Breast Department, Centre Eugène
Marquis, Rennes, FR

Matthew J. Ellis

Lester and Sue Smith Breast Center, Baylor Clinic,
Houston, US

Nagi S. El Saghir

NK Basile Cancer Institute, American University of Beirut
Medical Center, Beirut, LB

Alexandru Eniu

Department of Breast Tumors, Cancer Institute "I.
Chiricuta", Cluj-Napoca, RO

Lesley Fallowfield

Sussex Health Outcomes Research & Education in
Cancer, Brighton & Sussex Medical School, University of
Sussex, Brighton, UK

Prudence A. Francis

Division of Cancer Medicine, Peter MacCallum Cancer
Centre, Melbourne, AU

Karen Gelmon

Department of Medical Oncology, BC Cancer Agency,
Vancouver, CA

Mary K. Gospodarowicz

Department of Radiation Oncology, Princess Margaret
Hospital, University of Toronto, Toronto, CA

Renate Haidinger

Brustkrebs Deutschland e.V., Munich, DE

Stephen R.D. Johnston

Breast, Lung & Medical Oncology Services CBU, The
Royal Marsden NHS Foundation Trust and The Institute of
Cancer Research, London, UK

Bella Kaufman

Oncology Institute, Sheba Medical Center, Tel Hashomer, IL

Smruti Koppikar

Department of Oncology, Bombay Hospital Institute of Medical Sciences, Lilavati Hospital and Asian Cancer Institute, Mumbai, IN

Ian E. Krop

Breast Oncology Center, Dana-Farber Cancer Institute, Boston, US

Danni Manzi

Breast Cancer Care, London, UK

Norbert Marschner

Department of Hematology and Oncology, Outpatient Cancer Center, Freiburg, DE

Musa Mayer

Metastatic Breast Cancer Alliance, New York, US

Shirley A. Mertz

Metastatic Breast Cancer Network US, Inverness, US

Gertrude Nakigudde

Uganda Women's Cancer Support Organisation, Kampala, UG

Birgitte V. Offersen

Department of Oncology, Aarhus University Hospital, DK

Shinji Ohno

Breast Oncology Centre, Cancer Institute Hospital, Tokyo, JP

Olivia Pagani

Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, CH

Shani Paluch-Shimon

Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, IL

Frédérique Penault-Llorca

Department of Pathology, Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, FR

Aleix Prat

Hospital Clínic of Barcelona, University of Barcelona, Barcelona, ES

Hope S. Rugo

Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

Timo Schinköthe

CANKADO, Munich, DE

George W. Sledge

Division of Oncology, Stanford School of Medicine, Stanford, US

Danielle Spence

Breast Cancer Network Australia, Camberwell, AU

Christoph Thomssen

Clinic for Gynaecology, Martin-Luther-Universität, Klinikum Kröllwitz, Halle (Saale), DE

Nicholas C. Turner

Breast Cancer Now Research Centre at the Institute of Cancer Research, London, UK

Daniel A. Vorobiof

Sandton Oncology Centre, Johannesburg, ZA

Nikhil Wagle

Harvard Medical School, Dana-Farber Cancer Institute, Boston, US

Binghe Xu

Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

Breast cancer patient advocacy programme and Committee

Representatives of breast cancer patient advocacy groups were warmly invited to participate in ABC4 and actively contribute to the scientific programme and consensus session. Furthermore, in collaboration with the Breast Cancer Patient Advocacy Committee, including several leading breast cancer patient advocacy groups worldwide, specific additional patient advocacy sessions have been scheduled.



Brustkrebs
Deutschland e.V.
Prognose Leben



CENTRO DE APOIO A DOENTES COM CANCRO DA MAMA

Mama Help
Vai ver que faz sentido



METAVIVOR
Metastatic Breast Cancer Awareness, Research and Support



ULACCAM
Unión Latinoamericana
Contra el Cáncer de la Mujer

Coordinator: **Fatima Cardoso**

Breast Unit, Champalimaud Cancer Center, Lisbon, PT

Bertha Aguilar Lopez

ULACCAM, Mexico City, MX

Anna Cabanes

Susan G. Komen, Washington, US

Maria João Cardoso

MamaHelp Association, Lisbon, PT

Dian "CJ" M. Corneliussen-James

METAvivor Research and Support, Annapolis, US

Renate Haidinger

Brustkrebs Deutschland e.V., Munich, DE

Danni Manzi

Breast Cancer Care, London, UK

Musa Mayer

Metastatic Breast Cancer Alliance, New York, US

Shirley A. Mertz

Metastatic Breast Cancer Network US, Inverness, US

Gertrude Nakigudde

Uganda Women's Cancer Support Organisation,
Kampala, UG

Evi Papadopoulos

Europa Donna, Nicosia, CY

Danielle Spence

Breast Cancer Network Australia, Camberwell, AU

Chance to meet SPARC MBC Challenge awardees

Thursday 2 November | h. 12.40 | Location: Room 1.06

The SPARC Metastatic Breast Cancer Challenge, run by UICC and supported by a grant from Pfizer Oncology, is a first of its kind initiative to support organizations around the world address the specific needs of women with metastatic breast cancer. UICC and Pfizer invite ABC4 attendees to meet the 2015 and 2017 SPARC awardees to learn more about their projects.

ABC4 conference and consensus guidelines

The ABC guidelines are jointly developed by ESO and ESMO and are published simultaneously in *The Breast* and *Annals of Oncology* journals.

The Conference is endorsed by EUSOMA, FLAM, SIS/ISS, ESTRO, held with the support from BCRF and Susan G. Komen, under the auspices of OECI, UICC and with official representatives of ASCO.

The guidelines are endorsed by EUSOMA, FLAM, SIS/ISS and will be submitted for endorsement to ESTRO.

Details about the publication of the previous editions' guidelines at www.abc-lisbon.org



ABC Award

The ABC Award is aimed at recognising a researcher, physician, nurse or patient advocate who has made an outstanding and impacting contribution in the field of advanced breast cancer throughout his/her career.



The **ABC4 Award** - in recognition for her work and dedication to advocacy specifically to advanced breast cancer patients - will be assigned to **Musa Mayer** during the Award Ceremony on Thursday, 2 November.


The **ABC3 Award** - in recognition for his work on metastatic breast cancer, especially improving the management of metastatic cancer to bone, resulting in preservation and improvement in quality of life of patients worldwide - was assigned to Robert E. Coleman.



The **ABC2 Award** - in recognition of his work on discovering fundamental, clinically-relevant biological and molecular mechanisms for metastases including site specificity, latency, self-seeding and the role of the microenvironment in colonization and drug resistance - was assigned to Joan Massagué.



Floor plan





Bridging the Gap

Advanced Breast Cancer

Fifth International Consensus Conference

7-9 November 2019
Lisbon, Portugal

Coordinating Chair:
F. Cardoso, PT

RECEIVE UPDATES AT:
www.abc-lisbon.org • [#abclisbon](https://twitter.com/abclisbon)

SAVE THE DATE

Programme outline

Wed. 1 Nov	Thursday, 2 November		Friday, 3 November		Saturday, 4 November	Sunday, 5 November
14:00-17:00 REGISTRATION OPENS	9:00-19:30 Exhibition		9:00-19:30 Exhibition		8:30-13:00 Exhibition	8:30-13:00 First meeting of the ABC Global Alliance (part 2)
	9:00-10:30 Patient advocacy session: Direct patient involvement in ABC research	9:00-10:30 Sponsored satellite symposium	9:00-9:55 The new management of luminal ABC		8:30-10:30 Consensus session (part I)	
	Coffee break		Coffee break			
	10:20-11:30 Clinical challenges		Coffee break			
	11:00-12:30 Patient advocacy session: Survivorship 101: Work, finances, home and emotional support	11:00-12:30 Sponsored satellite symposium	11:30-12:25 Inflammatory advanced breast cancer		11:00-11:15 Report from ABC Patient Advocacy Committee	
	Coffee break		Coffee break		11:15-12:45 Consensus session (part II)	
	Lunch		Lunch and poster session		12:45-13:00 Close	
	13:30-14:30 Opening session and Keynote lecture		13:30-14:25 Lost in translation!			
	14:30-15:25 Long term remissions: Challenges and controversies		14:25-15:35 Supportive and palliative care		14:30 Lunch	
	15:25-16:05 Best abstract presentations		Coffee break		15:00-17:30 First meeting of the ABC Global Alliance (part 1)	
	Coffee break		16:00-17:00 A world of contrasts!			
	16:30-17:40 Optimizing anti-HER2 therapies for ABC		17:00-18:00 Management of triple negative ABC			
	17:40-18:00 ABC Award and lecture					
18:00-19:30 Patient advocacy session: Registries, databases and statistical modelling: making MBC count	18:00-19:30 Sponsored satellite symposium	18:00-19:30 Patient advocacy session: ABC Advocacy: Managing side effects, sexual issues and fertility	18:00-19:30 Sponsored satellite symposium			
Welcome cocktail (included in the registration fee)						

Programme

Thursday, 2 November

- 9:00-10:30**
Audit. II **Patient advocacy session:**
Direct patient involvement in ABC research
Chairs: Bertha Aguilar Lopez, MX - Anna Cabanes, US - Shirley A. Mertz, US
Panellists: Bertha Aguilar Lopez, MX - Jonas Bergh, SE - Matthew J. Ellis, US
Shirley A. Mertz, US - Danielle Spence AU - Nikhil Wagle, US
- 9:00-10:30**
Audit. I **Sponsored satellite symposium 1** (details are available on page 26)
- 10:30-11:00** Coffee break
- 11:00-12:30**
Audit. II **Patient advocacy session:**
Survivorship 101: Work, finances, home and emotional support
Chairs: Danni Manzi, UK - Gertrude Nakigudde, UG - Evi Papadopoulos, CY
- 11:00** - **Work means more than money**
Evi Papadopoulos, CY
 - 11:15** - **Discussion**
 - 11:30** - **The support of the other side**
Lesley Fallowfield, US
 - 11:45** - **Discussion**
 - 12:00** - **How can I swim in a storm**
Gertrude Nakigudde, UG
 - 12:15** - **Discussion**
- 11:00-12:30**
Audit. I **Sponsored satellite symposium 2** (details are available on page 26)
- 12:30** Lunch
- 12:40** UICC invites participants to Room 1.06 by the exhibition area to the event:
Chance to meet SPARC MBC Challenge awardees (see also page 10)
- 13:30**
Audit. I **Opening session**
Chairs: Fatima Cardoso, PT and Larry Norton, US
- 13:30** - **Welcome to Lisbon**
Prof. Marcelo Rebelo de Sousa, President of the Portuguese Republic
 - 13:40** - **Opening and introduction**
Fatima Cardoso, PT
 - 14:00** - **Keynote lecture - Living two roles: Oncologist and patient**
Bella Kaufman, IL
- 14:30-15:25**
Audit. I **Long term remissions: Challenges and controversies**
Chairs: Anna Cabanes, US and Olivia Pagani, CH
- 14:30** - **Management issues: How and until when to treat? [abstract IN03]**
Christoph Thomssen, DE
 - 14:45** - **Is family planning (fertility, adoption) out of the question? [abstract IN04]**
Shani Paluch-Shimon, IL

- 15:00 - **Impact on legal and professional lives [abstract IN05]**
Elizabeth Bergsten Nordström, SE
- 15:15 - **Discussion**
- 15:25-16:05 **Best abstract presentations**
Audit. I Chairs: Alberto Costa, IT/CH and Danielle Spence, AU
- 15:25 - **Analysis of the gaps on metastatic breast cancer global policies and advocacy efforts to support policy development across the patient journey [abstract OR33]**
Maia Thrift-Perry, US
- 15:35 - **Impact of disease progression status on time to deterioration of patient reported health related quality of life in first line er+ her2-ve advanced/metastatic breast cancer patients in the PALOMA-2 study [abstract OR65]**
Nadia Harbeck, DE
- 15:45 - **Effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients [abstract OR135]**
Eduardo Oliveira, PT
- 15:55 - **Discussion**
- 16:05 Coffee break
- 16:30-17:40 **Optimizing anti-HER-2 therapies for ABC**
Audit. I Chairs: Elzbieta Senkus, PL and Eric P. Winer, US
- 16:30 - **Optimal sequence with and without all available agents [abstract IN06]**
Ian E. Krop, US
- 16:45 - **Overcoming resistance to anti-HER2 therapies [abstract IN07]**
Karen Gelmon, CA
- 17:00 - **Potential role of immunotherapy [abstract IN08]**
Javier Cortés, ES
- 17:15 - **Will biosimilars become standard? [abstract IN09]**
Smruti Koppikar, IN
- 17:30 - **Discussion**
- 17:40-18:00 **ABC Award and lecture**
Audit. I **Silent voices speak: An advocate's journey [abstract IN01]**
Chair: Larry Norton, US - Awardee: Musa Mayer, US
- 18:00-19:30 **Patient advocacy session:**
Audit. II **Registries, databases and statistical modelling: Making MBC count**
Chairs: Musa Mayer, US and Danielle Spence, AU
- 18:00 - **Introduction and Australia STAR project**
Danielle Spence, AU
- 18:10 - **Estimation of the number of women living with metastatic breast cancer in the United States**
Musa Mayer, US
- 18:30 - **The new German cancer registry**
Norbert Marschner, DE
- 18:50 - **Breast Cancer Care UK**
Danni Manzi, UK
- 19:10 - **Discussion**
- 18:00-19:30 **Sponsored satellite symposium 3** (details are available on page 27)
Audit. I
- 19:30 Welcome cocktail (included in the registration fee)

Friday, 3 November

9:00-9:55 The new management of luminal ABC

Audit. I Chairs: Bertha Aguilar Lopez, MX and Binghe Xu, CN

- 9:00 - **Best sequence of available therapies [abstract IN10]**
Nadia Harbeck, DE
- 9:15 - **Management of new side effects [abstract IN11]**
Carlos H. Barrios, BR
- 9:30 - **Mechanisms of resistance to endocrine and biological agents [abstract IN12]**
Stephen R.D. Johnston, UK
- 9:45 - **Discussion**

9:55 Coffee break

10:20-11:30 Clinical challenges

Audit. I Chairs: Jonas Bergh, SE and Renate Haidinger, DE

- 10:20 - **Metronomic chemotherapy: A good old friend [abstract IN13]**
Nagi S. El Saghir, LB
- 10:35 - **Maintenance therapy (CT, ET, biologics) [abstract IN14]**
Prudence A. Francis, AU
- 10:50 - **Oral drugs: Challenges for the oncology nurse [abstract IN15]**
Christine B. Boers-Doets, NL
- 11:05 - **ABC elderly patient management [abstract IN16]**
Laura Biganzoli, IT
- 11:20 - **Discussion**

11:30-12:25 Inflammatory advanced breast cancer

Audit. I Chairs: Maria João Cardoso, PT and Gertrude Nakigudde, UG

- 11:30 - **Biology of inflammatory breast cancer [abstract IN17]**
Frédérique Penault-Llorca, FR
- 11:45 - **Extensive cutaneous metastases: A separate entity? [abstract IN18]**
Giuseppe Curigliano, IT
- 12:00 - **The role of different radiation techniques [abstract IN19]**
Birgitte V. Offersen, DK
- 12:15 - **Discussion**

12:25 Lunch and poster session (details available at page 21)

13:30-14:25 Lost in translation!

Audit. I Chairs: Dian "CJ" M. Corneliussen-James, US and Daniel A. Vorobiof, ZA

- 13:30 - **Multigene testing: Aid or clinical nightmare [abstract IN20]**
Fabrice André, FR
- 13:45 - **The role of ctDNA [abstract IN21]**
Nicholas C. Turner, UK
- 14:00 - **Precision/personalized medicine: Hopes & hypes [abstract IN22]**
George W. Sledge, US
- 14:15 - **Discussion**

14:25-15:35 Supportive and palliative care

Audit. I Chairs: Matti S. Aapro, CH and Musa Mayer, US

14:25 - **Management of neurotoxicity [abstract IN23]**

Matti S. Aapro, CH

14:40 - **Peritoneal carcinomatosis and ascites: Best practices [abstract IN24]**

Véronique Diéras, FR

- **End-of-life communication: Patient and health care provider perspectives**

14:55 **Part I [abstract IN25]** Lesley Fallowfield, UK

15:10 **Part II [abstract IN26]** Musa Mayer, US

15:25 - **Discussion**

15:35 Coffee break

16:00-17:00 A world of contrasts!

Audit. I Chairs: Fatima Cardoso, PT and Shirley A. Mertz, US

16:00 - **Access to radiation worldwide [abstract IN27]**

Mary K. Gospodarowicz, CA

16:15 - **Shortage of drugs: Solutions [abstract IN28]**

Alexandru Eniu, RO

16:30 - **eHealth: Friend or foe [abstract IN29]**

Timo Schinköthe, DE

16:45 - **Discussion**

17:00-18:00 Management of triple negative ABC

Audit. I Chairs: Shinji Ohno, JP and Evi Papadopoulos, CY

17:00 - **What's new in biology [abstract IN30]**

Aleix Prat, ES

17:15 - **The role of immunotherapy [abstract IN31]**

Hope S. Rugo, US

17:30 - **New kids on the block: CDKi, ARi, PARPi [abstract IN32]**

Lisa A. Carey, US

17:45 - **Discussion**

18:00-19:30 Patient advocacy session:

Audit. II **ABC Advocacy: Managing side effects, sexual issues and fertility**

Chairs: Dian "CJ" M. Corneliussen-James, US and Renate Haidinger, DE

18:00 - **How can physicians help to avoid or treat side effects?**

Christoph Thomssen, DE

18:15 - **How can patients help to avoid or treat side effects?**

Renate Haidinger, DE

18:30 - **Discussion**

18:45 - **Intimacy - starting over**

Dian "CJ" M. Corneliussen-James, US

19:00 - **Fertility - the joys and the risks**

Dian "CJ" M. Corneliussen-James, US

19:15 - **Discussion**

18:00-19:30 Sponsored satellite symposium 4 (details are available on page 27)

Audit. I

Saturday, 4 November

- 8:30-10:30** **Consensus session (part I)**
Audit. I ABC4 chairs, scientific committee members and panellists
- 10:30** Coffee break
- 11:00-11:15** **Report from ABC Patient Advocacy Committee**
Audit. I Danielle Spence, AU
- 11:15-12:45** **Consensus session (part II)**
Audit. I ABC4 chairs, scientific committee members and panellists
- 12:45-13:00** **Close**
Audit. I

A/V Recording during the Conference is prohibited.

Consensus panellists |

Matti S. Apro, CH
Bertha Aguilar Lopez, MX
Fabrice André, FR
Carlos H. Barrios, BR
Jonas Bergh, SE
Laura Biganzoli, IT
Christine B. Boers-Doets, NL
Fatima Cardoso, PT
Maria João Cardoso, PT
Lisa A. Carey, US
Javier Cortés, ES
Alberto Costa, IT/CH
Giuseppe Curigliano, IT
Veronique Diéras, FR
Nagi S. El Saghir, LB

Alexandru Eniu, RO
Lesley Fallowfield, UK
Prudence A. Francis, AU
Karen Gelmon, CA
Mary K. Gospodarowicz, CA
Nadia Harbeck, DE
Stephen R.D. Johnston, UK
Bella Kaufman, IL
Smruti Koppikar, IN
Ian E. Krop, US
Musa Mayer, US
Gertrude Nakigudde, UG
Larry Norton, US
Birgitte V. Offersen, DK
Shinji Ohno, JP

Olivia Pagani, CH
Shani Paluch-Shimon, IL
Evi Papadopoulos, CY
Frédérique Penault-Llorca, FR
Aleix Prat, ES
Hope S. Rugo, US
Elzbieta Senkus, PL
George W. Sledge, US
Danielle Spence, AU
Christoph Thomssen, DE
Daniel A. Vorobiof, ZA
Eric P. Winer, US
Binghe Xu, CN

First meeting of ABC Global Alliance



Despite some progress, too many people are still dying of advanced breast cancer (ABC) too early each year. The burden of the disease is expected to increase dramatically in the coming years with the developing world hit hardest.

With the advances in science, technology and communication tools, it is imperative that the cancer community around the globe joins forces to raise awareness of the disease and lobby for better outcomes for people living with ABC.

The ABC Global Alliance, established by the European School of Oncology, is a multi-stakeholder platform for all those interested in collaborating on common projects relating to ABC. Launched at the World Cancer Congress in 2016, its goal is to improve and extend the lives of women and men living with ABC in all countries worldwide and to fight for a cure.

The ABC Global Alliance invites all interested participants who are registered to attend the ABC4 Conference to join its first meeting which starts immediately after the ABC4 Conference and will be held in Auditorium VI across two half day sessions at the following times:

- **Part 1: Saturday, 4 November, from 15:00 to 17:30**, and
- **Part 2: Sunday, 5 November, from 8:30 to 13:00**

ABC4 registered participants are cordially invited to express interest in attending by contacting ABCGlobalAlliance@eso.net.

For further information, please visit www.abcgloballiance.org.

On behalf of everyone at the ABC Global Alliance, we look forward to welcoming you in Lisbon.

The ABC Global Alliance is an ESO initiative sponsored through unrestricted grants provided by AstaZeneca (Main Sponsor), Novartis (Main Sponsor), Pfizer (Main Sponsor) and Lilly (Sponsor).

Poster session

BP: Best poster presentation; PO: Poster presentation

- BP34** #Pacientesnocontrole (patients in control): Campaign to increase access to metastatic breast cancer (mbc) treatment in Brazil. Maira Caleffi, BR
- PO66** Adverse events (AE) of targeted agents added to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Matteo Lambertini, BE
- BP67** Characteristics of the metastatic breast cancer population with PIK3CA mutation in the randomized phase II study SAFIRO2 breast (UCBG- 0105/1304). Claudia Lefeuvre-Plesse, FR
- PO36** Fostering innovation in advocacy for metastatic breast cancer. Marina Teahon, CH
- PO37** Public hearings and debate cycles for parliamentarians on breast cancer. Maira Caleffi, BR
- PO38** A study of nursing provision and models of care for people diagnosed and living with metastatic breast cancer in Britain: what are the implications for the practice? and what role does patient advocacy play? Catherine Priestley, UK
- PO39** Educate-empower-advocate: A new model for advocacy and creating change for women with metastatic breast cancer. MJ DeCoteau, CA
- PO40** Patient navigation: Mitigating the surge of advanced breast cancer in sub-Saharan Africa. Runcie Chikeruba Wilson Chidebe, NG
- PO41** BC III and IV treatment in Brazil: Differences between public health, supplementary health and international protocol recommendations. Maira Caleffi, BR
- PO42** The unmet information, support and financial needs of women with metastatic breast cancer in Australia: results of two breast cancer network Australia studies. Danielle Spence, AU
- PO43** Tanto por hacer. Eliza Puente, MX
- PO44** Social media storytelling as an advocacy and support tool for people living with metastatic breast cancer. Janine Guglielmino, US
- PO45** Breast cancer knowledge and quality of life among participants of a breast cancer support group in rural Ruwanda. Thomas Albert Ndaysaba, RW
- PO46** Building a voice for metastatic breast cancer patients through a multi-year awareness campaign. Craig Faucette, CA
- PO47** Creating a novel drug navigation tool for metastatic breast cancer drugs in Canada. Craig Faucette, CA
- PO48** Share decision making for better patient participation in advanced breast cancer care. Marga Schrieks, NL
- PO50** Coping with metastatic breast cancer: the patients' perspective in a Brazilian cancer center. Maira Caleffi, BR
- PO51** Clinical study to improve patient-hcp communication & engagement for newly diagnosed metastatic breast cancer patients. Corrine Ellsworth Beaumont, US
- PO53** No lump required: a patient driven inflammatory breast cancer reserach initiative using the peer platform. Ginny Mason, US
- PO54** The world is not enough: the twilight of MBC patients' needs. Rania Azmi, KW
- PO57** Mesenchymal circulating tumour cell analysis to predict efficacy of eribulin for metastatic breast cancer patients. Yoshiya Horimoto, JP
- PO58** Regulation of stemness properties by ganoderma lucidum extract in inflammatory breast cancer cells via STAT3 regulation. Michelle MartinezMontemayor, PR
- PO59** IL-2 mediated improvement of cell antitumor activity in advanced breast cancer patients. Sandra Radenkovic, RS
- PO60** Influence of lipophilic components of matcha-tea extract on PPAR γ dependent cell proliferation. Lennard Schröder, DE
- PO61** The identification of the genes concerning to the distant metastasis of TNBC - the interaction with AR as an index. Noriko Miwa, JP
- PO63** Cancer associated fibroblasts display phenotypic and functional features that resemble circulating fibrocytes with constitute a nove subset of MDSCs. Gurcan Gunaydin, TR
- PO68** First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2-ABC: MANALEESA-2 safety results. Pierfranco Conte, IT
- PO69** Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice - results from the prospective German TMK cohort study. Norbert Marschner, DE

- PO70** Herceptin alone in comparison with herceptin combined everolimus in Asian patients with HER2+ breast cancer. Farrukh Djuraev, UZ
- PO71** ERBB2 amplification level and PTPN2 gain as potential prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab. Sander Ellegard, SE
- PO72** Triplet combination of endocrine therapy with CDK 4/6 inhibitor, ribociclib, and mTOR inhibitor, everolimus in HR+, HER2-ABC: results from the dose-expansion cohort. Aditya Bardia, US
- PO73** Efficacy and safety of palbociclib (PAL) plus fulvestrant (F) by geographic region in women with endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) from PALOMA-3. Nadia Harbeck, DE
- PO74** Efficacy and safety of platinum and metronomic cyclophosphamide in triple negative breast cancer. Giulia Viale, IT
- PO75** Retrospective analysis of advanced luminal breast cancer patients treated with endocrine therapy (ET) and palbociclib within a compassionate use programme. Christian Maurer, BE
- PO76** Preliminary data from a prospective non-interventional study to characterize real-world treatment patterns and outcomes of women with ER +/-HER2-advanced/ metastatic breast cancer. Nadia Harbeck, DE
- PO77** Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): When care objectives meet patients' need preliminary results of the VICTOR-6 study. Marina Elena Cazzaniga, IT
- PO78** Randomized prospective study: Paclitaxel every-3-weekly paclitaxel and versus weekly vinorelbine in metastatic breast cancer. Lika Katselashvili, GE
- PO79** Real world prescription patterns in metastatic HR+ breast cancer. Analysis from Instituto Nacional de Cancerologia, Mexico City. Claudia Arce Salinas, MX
- PO80** Efficacy of first line regimens in metastatic breast cancer patients. Real world evidence from Instituto Nacional de Cancerologia, Mexico City. Maria Tereza Nieto-Coronel, MX
- PO81** Ribociclib and endocrine therapy (ET) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER-2) breast cancer: The MONALEESA clinical trials program. Pierfranco Conte, IT
- PO82** A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive HR+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - vinometro. Christoph Thomssen, DE
- PO83** Prognostic factors in metastatic breast cancer patients to brain: retrospective analysis brain: retrospective analysis. Ahmed Gaballah, EG
- PO84** Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): Focus on luminal cancers. Results from GIM13-AMBRA study. Marina Elena Cazzaniga, IT
- PO85** Capecitabine and vinorelbine combination more effective as the first line treatment of advanced ER positive breast cancer. Loay Kassem, EG
- PO86** Efficacy and toxicity of eribulin in real-life non-selected advanced breast cancer patients. Anne Sofie Brems-Eskildsen, DK
- PO87** All oral combination of vinorelbine and capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC). Samir Shehata, EG
- PO88** Efficacy of capecitabine monotherapy as treatment for real life patients with HER2-negative metastatic breast cancer. Anne Sofie Brems-Eskildsen, DK
- PO90** Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: real life experience. Elena Kovalenko, RU
- PO91** Relapse and metastatic spread patterns in patients with HER2/neu positive breast cancer who underwent targeted therapy. Ekaterine Arkanian, GE
- PO92** Evaluation of pertuzumab treatment for metastatic breast cancer in a retrospective single institution study. Mitsugu Yamamoto, JP
- PO93** Leptomeningeal metastases from breast cancer - are we overtreating? decision algorithms and assuring breast care. Ana Leonor Matos, PT
- PO94** Treatment of advanced breast cancer with T-DM1 in a cancer center. Filipa Ferreira Pereira, PT
- PO95** Patterns of response to therapy in ER/PR positive metastatic breast cancer. Marie Sundquist, SE
- PO96** Advanced breast cancer in young women: outcome of a Portuguese hospital. David da Silva Dias, PT

- PO100** Gastrointestinal and other selected adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: A systematic review and meta-analysis. Kyrillus Shohdy, EG
- PO112** Breast cancer liver metastases - when to operate. Vitor Devezas, PT
- PO113** GISEL study group proposal: a phase II randomized clinical trial in breast cancer patients with skin metastases treated with or without electrochemotherapy (ECT) during the first line of treatment. Roberto Agresti, IT
- PO114** Metastatic breast cancer patients who achieved clinical complete response after multidisciplinary therapy: clinical features from a single institution. Haruko Takuwa, JP
- PO115** A novel and innovative "non-tunneling" technique of port insertion for chemotherapy infusion in advance breast cancer patients: a single center study in 130 patients. Abhinav Deshpande, IN
- PO117** Electrochemotherapy (ECT) treatment in-patient with bone foot metastasis from breast: A case report. Daniele Screpis, IT
- PO118** Five years overall survival of locally advanced triple-negative breast cancer in west Sumatera, Indonesia. Daan Khambri, IN
- PO121** A retrospective cohort study to investigate association between preferences for future care and period of final chemotherapy administration before end-of-life. Sena Yamamoto, JP
- PO122** Advanced stage breast cancer lifestyle and exercise (ABLE) feasibility study: Preliminary results. Lidia Delrieu, FR
- PO123** Leaving a legacy: Half day retreat for young women living with metastatic breast cancer. Mary Ajango, US
- PO125** The information and support needs of women with metastatic breast cancer who have dependant aged children: A study to inform service development to support women talk with and prepare their children. Maria Leadbeater, UK
- PO126** Quality of life and psychosocial need of metastatic breast cancer patients. Tahir Mehmood, PK
- PO127** Palliative care in Egypt: Challenges and opportunities. Mohamed Hablas, EG
- PO128** G-CSF and G-CSF biosimilars: A meta-analysis of randomized clinical trials in breast cancer patients undergoing myelosuppressive chemotherapy. Giuseppe Curigliano, IT
- PO129** Musculoskeletal pain and health-related quality of life among breast cancer patients: Evidence from south India. Asmin Sha, IN
- PO130** Utilization of integrative supportive services in a specialized advanced breast cancer center. Timothy J. Pluard, US
- PO131** Predictive factors for persistent pain in patients with advanced breast cancer receiving adjuvant therapy. Teodora Alexa-Stratulat, RO
- PO132** Evaluation of health-related quality of life via the computer-based health evaluation system (CHES) for Japanese metastatic breast cancer patients: A single-center pilot study. Yuichiro Kikawa, JP
- PO133** Exploring support networks and quality of life of metastatic breast cancer patient in Nigeria and Turkey. Runcie Chikeruba Wilson Chidebe, NG
- PO134** Homestatic correlations in patients with breast and ovarian cancer. Elina Beleva, BG
- PO136** First-line treatment modality for metastatic breast cancer: A single-institution outcome analysis by metastatic site and molecular type. Russell Burcombe, UK
- PO137** Presentation and specific risk factors of inflammatory breast cancer (IBC): a multicenter Tunisian study. Nesrine Mejri Turki, TU
- PO138** Preference of treatment decision-making in women with advanced breast cancer. Chikako Shimizu, JP
- PO139** An investigation into the psycho-social benefits of women attending UK charity breast cancer care's "living with secondary breast cancer" service: A group based psycho-educational intervention. Catherine Priestley, UK
- PO140** Rise of metastatic breast cancer incidence in Lebanon: Effect of refugees and displaced people from Syria, and patients from war-torn Iraq. Nagi S. El Saghir, LB
- PO141** Adjuvant therapies for breast cancer improve cure rates but appear to shorten post-metastatic survival. Nadia Harbeck, DE
- PO142** Advanced breast cancer prevalence and related personal factors. Nanuli Ninashvili, GE
- PO143** Inflammatory breast cancer: A single center experience from developing country. Pooja Khullar, IN
- PO144** Clinicopathological characteristics, prognosis and issues in young women (<40 years old) with recurrent or metastatic breast cancer. Kaori Ushimado, JP
- PO145** Harvesting population data to aid treatment decisions in heavily pre-treated advanced breast cancer. Sharon Hensley Alford, US

Abstract presenters

Roberto Agresti, Istituto Nazionale dei Tumori, Breast Surgery Unit, Milan, IT
Mary Ajango, Young Surviva Coalition, National Programs Department, New York, US
Teodora Alexa-Stratulat, Regional Institute of Oncology, Medical Oncology Department, Iasi, RO
Claudia Arce Salinas, Instituto Nacional de Cancerologia, Medical Oncology Department, Mexico City, MX
Ekaterine Arkania, Institute of Clinical Oncology, Chemotherapy and Clinical Research Department, Tblisi, GE
Rania Azmi, Fadia Survive & Thrive Association, MBC Patients Advocacy, Kuwait City, KW
Aditya Bardia, Massachusetts General Hospital, Harvard Medical School, Harvard, US
Elina Beleva, Medical University Plovdiv and University Hospital Sveti Georgi, Clinical Oncology Department and Clinic of Medical Oncology, Plovdiv, BG
Anne Sofie Brems-Eskildsen, University Hospital of Aarhus, Oncology Department, Aarhus, DK
Russell Burcombe, Kent Oncology Center, Maidstone & Tunbridge Wells NHS Trust, Maidstone, UK
Maria Caleffi, FEMAMA, Management Department, Porto Alegre, BR
Marina Elena Cazzaniga, ASST Monza, Research Unit, Phase I trials and Medical Oncology, Monza, IT
Runcie Chikeruba Wilson Chidebe, Project Pink Blue Health & Psychological Trust Center, Patient Advocacy and Research Abuja, NG
Pierfranco Conte, Istituto Oncologico Veneto, Division of Medical Oncology, Padua, IT
Giuseppe Curigliano, European Institute of Oncology, Division of Experimental Therapeutics, Milan, IT
David da Silva Dias Centro Hospitalar Do Algarve, Medical Oncology Department, Faro, PT
MJ DeCoteau, Rethink Breast Cancer Breast Cancer Department, Toronto, CA
Lidia Delrieu, University Claude Bernard and Leon Berard Cancer Center, Inter-University Laboratory of Human Movement Biology and Department of Cancer and Environment, Villeurbanne and Lyon FR
Abhinav Deshpande, Gujarat Cancer and Research Institute, Surgical Oncology Department, Ahmedabad, IN
Vitor Devezas, Centro Hospitalar de Sao Joao, General Surgery Department, Porto, PT
Farrukh Djuraev, Tashkent Medical Academy, Department of Oncology, Tashkent, UZ
Nagi S. El Saghir, American University of Beirut Medical Center, Naef K. Basile Cancer Center, Beirut, LB
Sander Ellegard, University Hospital of Linköping, Oncology Department, Linköping, SE
Corrine Ellsworth Beaumont, Worldwide Breast Cancer, Executive Department, Lewisville, US
Craig Faucette, Canadian Breast Cancer Network, Operations Department, Ottawa, CA
Filipa Ferreira Pereira, Instituto Portugues de Oncologia do Porto, Medical Oncology Department, Porto, PT
Ahmed Gaballah, Ain Shams University Hospital, Department of Clinical Oncology, Cairo,
Janine Guglielmino, Living Beyond Breast Cancer, Programms and Partnerships Department, Bala Cynwyd, US
Gurcan Gunaydin, Hacettepe University Cancer Institute, Department of Basic Oncology, Ankara, TR
Mohamed Hablas, Gharbia Cancer Society, Medical Oncology and Palliative Care Department, Tanta, EG
Nadia Harbeck Brustzentrum der Unirsitaet Muenchen (LMU), Obstetrics and Gynaecological Department, Munich, DE
Sharon Hensley Alford, IBM, Watson Health, Dearborn, US
Yoshiya Horimoto, Juntendo University School of Medicine, Department of Breast Oncology, Tokyo, JP
Loay Kassem, Kasr El Aini, Department of Clinical Oncology and Nuclear Medicine, Cairo, EG
Lika Katselashvili, Research Institute of Clinical Medicine, Oncology Department, Tblisi, GE
Daan Khambri, Dr. M. Djamil Hospital, Oncology Division, Padang, IN

Pooja Khullar, Batra Hospital and Medical Research Centre, Radiation Oncology Department, New Dehli, IN
 Yuichiro Kikawa, Kobe City Medical Center General Hospital, Department of Breast Surgery, Kobe-City, JP
 Elena Kovalenko, Russia Oncology Center Named after NN Blochin, Chemotherapy Department, Moscow, RU
 Matteo Lambertini, Institut Jules Bordet, Breast Cancer Translational Research Laboratory, Brussels, BE
 Maria Leadbeater, Chesterfield Royal Hospital, Macmillan Cancer Centre, Calow, UK
 Claudia Lefeuvre-Plesse, Centre Eugene Marquis, Medical Oncology Department, Rennes, FR
 Norbert Marschner, Praxis für interdisziplinäre Onkologie & Hämatologie, Oncology Department, Freiburg, DE
 Michelle Martinez-Montemayor, Universidad Central del Caribe, School of Medicine, Department of Biochemistry, Bayamon, PR
 Ginny Mason, IBC Research Foundation, West Lafayette, US
 Ana Leonor Matos Hospital Sao Francisco Xavier, Internal Medicine and Medical Oncology Department, Lisbon, PT
 Christian Maurer, Institut Jules Bordet, Oncology Clinic, Breast Department, Brussels, BE
 Tahir Mehmood, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Radiation Oncology Department, Lahore, PK
 Nesrine Mejri Turki, Abderrahmen Mamo Hospital, Department of Medical Oncology, Ariana, TU
 Noriko Miwa, Nishiwaki Municipal Hospital, Breast Surgical Oncology Department, Nishiwaki, JP
 Thomas Albert Ndaysaba, Partners in Health, Poser - Programme on social and economic rights, Kigali, RW
 Maria Tereza Nieto-Coronel, Instituto Nacional de Cancerologia, Medical Oncology Department, Mexico City, MX
 Nanuli Ninashvili, Tbilisi State Medical University, Epidemiology and Biostatistics Department, Tbilisi, GE
 Eduardo Oliveira, Mama Help, Physical Exercise Department, Porto, PT
 Timothy J. Pluard, Saint Luke's Cancer Institute, Koontz Center for Advanced Breast Cancer, Kansas City, US
 Catherine Priestley, Breast Cancer Care, Nursing Department, London, UK
 Eliza Puente, Asociacion Mexicana contra el cancer de mama AC, Management Department, Mexico City, MX
 Sandra Radenkovic, Institute of Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, RS
 Marga Schrieke, Dutch Breast Cancer Patient Organisation, Quality of Care Department, Utrecht, NL
 Lennard Schröder, Ludwig Maximilian University, Gynecology and Obstetrics Department, Munich, DE
 Daniele Screpis, Sacro Cuore Hospital, Orthopedic Department, Negrar, IT
 Asmin Sha, Al Iqbal Hospital, Pathology Department, Thrissur, IN
 Samir Shehata, Assiut University, Medical Oncology Department, Assiut, EG
 Chikako Shimizu, National Cancer Center Hospital, Department of Breast and Medical Oncology, Tokyo, JP
 Kyrillus Shohdy, Kasr Alainy School of Medicine, Clinical Oncology Department, Cairo, EG
 Danielle Spence, Breast Cancer Network Australia, Policy Department, Carberwell, AU
 Marie Sundquist, County Hospital, Breast Unit, Kalmar, SE
 Haruko Takuwa, Shiga Medical Center for Adults, Breast Surgery Department, Moriyama-shi, JP
 Marina Teahon, Union for International Cancer Control (UICC) Capacity Building Department, Geneva, CH
 Christoph Thomssen, Martin Luther University Halle-Wittenburg, Department of Gynecology, Halle, DE
 Maia Thrift-Perry, Pfizer, International Public Affairs Department, New York, US
 Kaori Ushimado, Fujita Health University, Breast Surgery Department, Aichi, JP
 Giulia Viale, European Institute of Oncology, Division of Early Drugs Development, Milan, IT
 Mitsugu Yamamoto, Hokkaido Cancer Center, Department of Breast Surgery, Sapporo, JP
 Sena Yamamoto, Social Medical Cooperation Hakuai, Sagara Hospital Department of Nursing, Kagoshima, JP

Sponsored satellite symposia

Thursday, 2 November

9:00-10:30
Audit. 1

Sponsored satellite symposium 1 - **AstraZeneca**
Illuminating a new pathway in breast cancer



- 9:00 - **The guiding light – meeting the needs of the patient**
- 9:05 - **Welcome and introduction**
Christian Jackisch, DE
- 9:10 - **Highlighting a new target in breast cancer – DNA damage response**
Cristina Cruz, ES
- 9:25 - **Shining the light on a new breast cancer paradigm**
Sibylle Loibl, DE
- 9:35 - **Opportunity for questions**
Chair: Christian Jackisch, DE
- 9:45 - **PARP inhibitors – a spark for change in breast cancer management**
Pierfranco Conte, IT
- 10:05 - **In the spotlight – the use of *BRCA* in clinical practice**
Panel discussion – Chair: Sibylle Loibl, DE
- 10:15 - **Opportunity for questions**
Chair: Christian Jackisch, DE
- 10:25 - **Summary and close**
Christian Jackisch, DE

Symposium faculty:


Cristina Cruz, Institute of Oncology, Barcellona, Spain

Pierfranco Conte, Istituto Oncologico Veneto, Padova, Italy

Christian Jackisch, Sana Klinikum Offenbach, Offenbach, Germany

Sibylle Loibl, German Breast Group, Neu-Isenburg, Frankfurt, Germany

11:00-12:30
Audit. 1

Sponsored satellite symposium 2 - **Novartis**  **NOVARTIS**
Patient-centric treatment decisions in clinical practice:
Harnessing the power of combination therapy
Chair: Diana Lüftner, DE

- 11:00 - **Joining forces for efficacy:**
The current state of targeted therapy for HR+, HER2– advanced breast cancer
Chair: Diana Lüftner, DE | Speaker: Luis Costa, PT
- 11:15 - **Patterns, combinations, and sequences:**
Case-based discussion on treatment decisions for HR+, HER2 – Advanced Breast Cancer
Case Presenter and Moderator: Diana Lüftner, DE
Panelists: Luis Costa, PT - Guenther Steger, AT
- 12:10 - **Q & A discussion**
Moderator: Guenther Steger, AT
- 12:20 - **Forging future understandings**
Speaker: Luis Costa, PT

Symposium faculty:**Luis Costa**, Hospital Santa Maria, Lisbon, Portugal**Diana Lüftner**, Humboldt University, Berlin, Germany**Guenther Steger**, Medical University of Vienna, Vienna, Austria**18:00-19:30**
Audit. 1Sponsored satellite symposium 3 - **Pfizer****A united vision for mBC:****changing the treatment paradigm with CDK4/6 inhibitors**

Chair: Antonio Llombart-Cussac, ES

- 18:00** - **Welcome and introduction**
Antonio Llombart-Cussac, ES
- 18:05** - **A united vision: guiding principles in the management of breast cancer**
Günther Steger, AT
- 18:35** - **Challenging current perceptions in HR+/HER2- mBC**
Antonio Llombart-Cussac, ES
- 18:55** - **A glimpse into the therapy management of CDK4/6 inhibitors**
Johannes Ettl, DE
- 19:15** - **Panel discussion and Q&A**
All faculty
- 19:25** - **Closing remarks**
Antonio Llombart-Cussac, ES

Symposium faculty:**Johannes Ettl**, Technical University of Munich, Munich, Germany**Antonio Llombart-Cussac**, University Hospital Arnau de Vilanova, Valencia, Spain**Günther Steger**, Medical University of Vienna, Vienna, Austria**Friday, 3 November****18:00-19:30**
Audit. 1Sponsored satellite symposium 4 - **Celgene****The evolving sequence of therapies, moving forward in mBC:****All chemotherapies are not created equally**

Chair: Grazia Arpino, IT



- 18:00** - **Welcome and objectives**
Grazia Arpino, IT
- 18:05** - **Interactive patient case series: Improving how we manage patients with mBC**
Marina Cazzaniga, IT - Eva Ciruelos, ES - Frederik Marme, DE
 - Indolent mBC: Are we making optimal use of all our treatment options?
 - Rapidly progressive mBC: Identifying the correct treatment sequence in these challenging patients
 - Treating triple negative mBC: Clinical considerations for the use of Abraxane

- 19:05 - Improving disease outcomes in patients with mBC:
Choosing the right algorithm
Panel and audience discussion of the patient case study series
- 19:25 - Summary and close
Grazia Arpino, IT

Symposium faculty:

Grazia Arpino, University of Naples Federico II, Italy

Marina Cazzaniga, San Gerardo Hospital, Monza, Italy

Eva Ciruelos, University Hospital 12 de Octubre, Madrid, Spain

Frederik Marme, Universität Heidelberg, Heidelberg, Germany

Sponsors

(as of 12 October)

ESO wishes to express its appreciation for the following sponsors for having granted their participation and support to ABC4.

Travel grants, support to the Conference and to the patient advocacy activities



Participating organisations and companies



Pierre Fabre
Oncology

Disclosure of conflict of interest

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the conference. Potential conflict of interest are considered any of the following: Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the consensus process. Any financial interest in or arrangement with a competing company. Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presenter or in the participation in the consensus process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

ABC4 Chairs, Co-Chairs, Scientific Committee Members, faculty and panel members

Matti S. Aapro: Receipt of grants/research supports: Amgen, Helsinn, Pfizer, Sandoz, TEVA, VIFOR. Receipt of honoraria or consultation fees: Amgen, Angelini, Helsinn, Kirin, Pfizer, Sandoz, Taiho, TEVA, VIFOR. Participation in a sponsored speakers' bureau: Helsinn, Pfizer, Sandoz, Taiho, TEVA.

Bertha Aguilar Lopes: No significant relationships.

Fabrice André: Receipt of grants/research supports: AstraZeneca, Novartis, Pfizer, Lilly.

Carlos H. Barrios: Receipt of grants/research support: Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Taiho Pharmaceutical, Mylan, Merrimack, Merck, Abbvie, Astellas Pharma, Biomarin, Bristol Myers Squibb, Daiichi Sankyo, Abraxis BioScience, AB Science, Asana Biosciences, Medivation, Exelius, ImClone Systems, LEO Pharma, Millenium. Receipt of honoraria or consultation fees: Boehringer Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai.

Jonas Bergh: Receipt of grants/research support: Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, Sanofi-Aventis to Karolinska Institutet/University Hospital. No personal payments. Payment to Asklepios HB for a chapter in UpToDate on breast cancer.

Elizabeth Bergsten Nordström: No significant relationships.

Laura Biganzoli: Receipt of grants/research support: Celgene. Receipt of honoraria or consultation fees: Eisai, AstraZeneca, Ipsen, Roche, Novartis.

Christine B. Boers-Doets: Receipt of grants/research

support: Bayer, Novartis, Pfizer, Roche, EusaPharma, Amgen, GSK. Amgen, AstraZeneca, Baxalta, Bayer, Becton, Dickinson, bioXtra, Boehringer Ingelheim, Bristol Myers Squibb, EusaPharma, Galera, GlaxoSmithKline, Helsinn, MerckSerono, Merck Sharp & Dohme, Shire, Nordic Pharma, Novartis, Pfizer, Roche, Takeda.

Anna Cabanes: Receipt of grants/research support: Pfizer Inc, Merck, Caterpillar, GE.

Fatima Cardoso: Receipt of honoraria or consultation fees: Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), MacroGenetics, Merck-Sharp, Merus BV, Mylan, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Teva.

Maria João Cardoso: No significant relationships.

Lisa A. Carey: No significant relationships.

Dian "CJ" M. Corneliussen-James: No significant relationships.

Javier Cortés: Receipt of honoraria: Roche, Novartis, Eisai, Celgene, Pfizer. Consulting/advisor: Roche, Celgene, AstraZeneca, Cellectia Biotech, Biothera.

Alberto Costa: No significant relationships.

Giuseppe Curigliano: Receipt of honoraria or consultation fees: Roche, Pfizer.

Véronique Diéras: Receipt of honoraria or consultation fees for advisory boards: Roche, Novartis, Pfizer, Lilly, Abbvie. Participation in a sponsored speaker's bureau: Roche, Pfizer.

Nagi S. El Saghir: Receipt of grants/research support: Novartis (to institution). Receipt of honoraria or consultation fees: Novartis, Roche, Pfizer, Lilly; MSD.

Matthew J. Ellis: Receipt of grants/research support: Pfizer. Receipt of honoraria or consultation fees: Pfizer, Astra Zeneca, Novartis, Puma. Stock shareholder: Bioclassifier LLC, Prosigna.

Alexandru Eniu: Receipt of grants/research support: Astra Zeneca, Roche, Celltrion, Pfizer.

Lesley Fallowfield: No significant relationships.

Prudence A. Francis: Receipt of honoraria or consultation fees: AstraZeneca. Other support: Overseas speaker for Pfizer.

Karen Gelmon: Receipt of grants/research support: AstraZeneca, Pfizer, BMS. Receipt of honoraria or consultation fees: Merck, AstraZeneca, Novartis, BMS.

Mary K. Gospodorowicz: No significant relationships.

Renate Haidinger: No significant relationships.

Nadia Harbeck: Receipt of honoraria or consultation fees: Amgen, Celgene, Novartis, Pfizer, Roche, Sandoz.

Stephen R.D. Johnston: Receipt of grants/research support: Pfizer, GlaxoSmithKline. Receipt of honoraria or consultation fees: AstraZeneca, Pfizer, Novartis. Participation in a sponsored speaker's bureau: Pfizer, Puma, OBI.

Bella Kaufman: Not received.

Smruti Koppikar: Advisory board: Roche, Eli Lilly, Boehringer Ingelheim, MSD, Merck Serono, Myelan, Reddy.

Ian E. Krop: Receipt of grants/research support and receipt of honoraria or consultation fees: Genentech.

Danni Manzi: No significant relationships.

Norbert Marschner: Stock shareholder: Iomedico AG. Other support: Iomedico AG is supporter of the trial.

Musa Mayer: No significant relationships.

Shirley A. Mertz: Receipt of honoraria and consultation fees: Novartis, Pfizer.

Gertrude Nakigudde: Receipt of grants/research support: UICC SPACC grant, Pfizer.

Larry Norton: No significant relationships.

Birgitte V. Offersen: No significant relationships.

Shinji Ohno: Participation in a sponsored speaker's bureau: AstraZeneca, Novartis, Chugai, Eisai, Taiho, Kyowa-Kirin.

Olivia Pagani: No significant relationships.

Shani Paluch-Shimon: No significant relationships.

Evi Papadopoulos: No significant relationships.

Frédérique Penault-Llorca: Receipt of grants/research support: Roche, BMS, AstraZeneca. Receipt of honoraria or consultation fees: Roche, Novartis, BMS, AstraZeneca, MSD.

Alex Prat: Receipt of honoraria or consultation fees: Nanostring technologies.

Hope S. Rugo: Receipt of grants/research support: Genentech/Roche, Novartis, Eisai, OBI, Plexxikon, Merck, MacroGenics, Pfizer, Lilly.

Timo Schinköthe: No significant relationships.

Elzbieta Senkus: Receipt of grants/research support: Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Pierre Fabre, Roche. Other support (travel expenses) Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Novartis, Roche.

George W. Sledge: Receipt of honoraria or consultation fees: Symphogen. Stock Shareholder: Syndax.

Danielle Spence: No significant relationships.

Christoph Thomssen: Receipt of honoraria and consultation fees: Amgen, Astra Zeneca, Celgene, Nanostring, Novartis, Pfizer, Roche.

Nicholas C. Turner: Not received.

Daniel A. Vorobiof: Receipt of honoraria and consultation fees: Pfizer, BMS, MSD, AstraZeneca, Eisai, Roche. Participation in a sponsored speaker's bureau: BMS, MSD, Roche.

Nikhil Wagle: Receipt of grants/research support: Novartis, Merck, Puma. Receipt of honoraria and consultation fees: Novartis, Grail. Stock shareholder: Foundation medicine.

Eric P. Winer: Receipt of grants/research support: Genentech. Receipt of honoraria and consultation fees: Genentech, Tesaro. Advisory board: Leap.

Binghe Xu: No significant relationships.



20-24 April 2018
Barcelona, Spain

SESSIONS ON BREAST CANCER

Saturday 21 April 2018

Teaching lecture → 8.00 - 8.40 hrs

Optimal sequence in the treatment of breast cancer: radiotherapy first?

Symposia → 8.45 - 10.00 hrs

More of both? Breast reconstruction and regional lymph node irradiation

→ 10.00 - 10.30 hrs

Improving radiation therapy in breast cancer by avoiding side effects

Multidisciplinary tumour board session on breast cancer → 13.00 - 14.30 hrs

Early registration:
17 January 2018

WWW.ESTRO.ORG
#ESTRO37

 **ESTRO**
European Society for
RADIOTHERAPY
& ONCOLOGY

EBCC

European
Breast Cancer
Conference

11



"Estudio de luz" by Ramón Casas © Museo de Bellas Artes de Asturias. Pedro Masaveu Collection

European Breast Cancer Conference

Together, a major step forward

Be part of a unique gathering of physicians, scientists and patients.

KEY DATES



2017

- **15 Nov:** Abstract submission deadline

2018

- **1 Feb:** Late-breaking abstract submission opens
- **5 Feb:** Regular-rate registration deadline
- **15 Feb:** Late-breaking abstract submission deadline



 #EBCC11  www.ecco-org.eu/EBCC

BARCELONA
SPAIN

21 – 23 MARCH
2018



ulm university universität
uulm

CERTIFICATE OF COMPETENCE IN BREAST CANCER

THIRD COHORT 2019-2020

The European School of Oncology in co-operation with Ulm University offers a structured Certificate of Competence in Breast Cancer Programme, an academically recognised curriculum of studies, which was developed with the contribution of internationally recognised physicians and scientists in the field of breast cancer.

PROGRAMME

The Programme, which is offered on a part-time basis using blended-learning modules and seminars, is divided in **three attendance seminars** (in Austria, Portugal and Germany) and **five e-learning modules**.

Over the duration of **13 months** the Programme provides a total of 381 hours of comprehensive learning, accordingly reported with a workload of 13 European Credit Transfer and Accumulation System Points (ECTS) by Ulm University. The current edition started in March 2017 and will conclude in April 2018.

ELIGIBILITY

The Programme is designed for **physicians with experience in the field of breast cancer** (medical oncology, radiation oncology, gynaecology, senology, pathology), but it is equally accessible to graduates in **natural sciences** who are engaged in the field of breast cancer.

ADMISSION AND DEADLINES

Admission to the Certificate of Competence in Breast Cancer Programme is by competitive application only and the selection is based on eligibility criteria and the selection procedure.

Attendance is limited to **20 participants** per cohort.

Applications for the third edition will open in mid-May 2018 and submission is required by the deadline of **14 September 2018**.

CERTIFICATE

Upon successful completion of the Programme, participants will obtain an academic certificate issued by the European School of Oncology and Ulm University assigning **13 ECTS** and a diploma supplement by Ulm University.

Chairs:

F. Cardoso, PT

J. Huober, DE

W. Janni, DE

O. Pagani, CH

F.A. Peccatori, IT

E.P. Winer, U

**FURTHER
INFORMATION AT
WWW.ESO.NET**



Breast Centres Network

Synergy among Breast Units

A project of



Need to quickly contact a breast expert colleague?

Is your Breast Unit organised according to state-of-the-art international standards?

Don't miss the opportunity to discover more and improve your Breast Unit!



Become a Breast Centres Network Member

www.BreastCentresNetwork.org

Membership is free!

Breast Centres Network is the first international network of clinical centres exclusively dedicated to the diagnosis and treatment of breast cancer. It is a project of ESO (European School of Oncology) with the aim to promote and improve breast cancer care in Europe and throughout the world.

Our network includes Breast Units (Multidisciplinary Breast Centres) that fulfill minimum requirements (see Eligibility Gate) to be considered referral centres. Organisation of Multidisciplinary Breast Units is recommended by EUSOMA, Europa Donna (European Breast Cancer Coalition) and the European Parliament. In the US, breast center accreditation is offered by the National Accreditation Program for Breast Centers.

We offer an online Breast Unit Directory that provides detailed information at a glance about our members in an attempt to broadcast the state-of-the-art international standards for multidisciplinary breast cancer care.

**More than
200 centres
online!**

**And it'll really make a
difference to your center!**

**GO SOCIAL!
#BCN_ESO**

Improving and extending the lives
of women and men living with
advanced breast cancer (ABC)
in all countries worldwide
and fighting for a cure

The ABC Global Alliance is a multi-stakeholder platform
for all those interested in collaborating
in common projects relating to advanced breast cancer (ABC).



We invite individuals and organisations interested
in advanced breast cancer to join our efforts!

The ABC Global Alliance is an ESO initiative



also sponsored through unrestricted grants provided by:

Main sponsors: AstraZeneca  Pfizer  Oncology  NOVARTIS

Sponsor: *Lilly*

www.abcgloballiance.org
ABCglobalalliance@eso.net



FIND US ON
@ABCGlobalAll



BCY4

4TH ESO-ESMO BREAST CANCER IN YOUNG WOMEN INTERNATIONAL CONFERENCE

**6-8 October 2018
Lugano, Switzerland**

Chair:
O. Pagani, CH

IMPORTANT DEADLINES

- Abstracts: **6 May 2018**
- Early registration: by **17 June 2018**
- Late registration: by **23 September 2018**
- On-site registration: from **24 September 2018**

ORGANISING SECRETARIAT: European School of Oncology (ESO) | Via Turati, 29 | 20121 Milan | Italy | fmarangoni@eso.net

Further information available at www.eso.net | Follow us on



#BCYlugano



INSIDE TRACK CONFERENCE